<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000662028"><TermName>veltuzumab</TermName><TermPronunciation>(vel-TOO-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of several types of lymphoma. It binds to the protein CD20, which is found on B cells (a type of immune system cell) and some types of lymphoma cells. This causes the immune system to kill the cancer cells. Veltuzumab is a type of monoclonal antibody. Also called hA20, HCD20,  and IMMU-106.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000726029" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;veltuzumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000726028" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;veltuzumab&quot;" language="es" id="_4"/><SpanishTermName>veltuzumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de linfoma. Se une a la proteína CD20, que se encuentra en las células B (tipo de célula del sistema inmunitario) y a algunos tipos de células de linfomas. Hace que el sistema inmunitario destruya las células cancerosas. El veltuzumab es un tipo de anticuerpo monoclonal. También se llama hA20, HCD20,  y IMMU-106.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-04-07</DateFirstPublished><DateLastModified>2010-04-07</DateLastModified></GlossaryTerm>
